Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Hope to see the quarterly after the close today...

While I rarely disagree with you, I guess I'll have to on this one. The last sentence seems crystal clear to me in that it states that complying with 12b-25 = timely filed.

Regarding our early filer status, that has to do with our market value, not an enforcement action.

From Rule 12b-2

The term "accelerated filer" means an issuer after it first meets the following conditions as of the end of its fiscal year:

  1. The issuer had an aggregate worldwide market value of the voting and non-voting common equity held by its non-affiliates of $75 million or more, but less than $700 million, as of the last business day of the issuer?s most recently completed second fiscal quarter;

  2. The issuer has been subject to the requirements of section 13(a) or 15(d) of the Act for a period of at least twelve calendar months;

  3. The issuer has filed at least one annual report pursuant to section 13(a) or 15(d) of the Act; and

  4. The issuer is not eligible to use Forms 10-KSB and 10-QSB for its annual and quarterly reports.

Share
New Message
Please login to post a reply